# Q500 verify report, round 4: s62, Abdominal pain

Fresh independent review by Preceptor of the whole final text of `src/samps/s62/abdominal-pain.ts` (abdominal-pain-48 to abdominal-pain-52) after the round-4 writer revision ("Round 4" in `docs/reviews/q500-writer-s62-r2.md`). The reviewer did not write, edit or review this batch before. No SAMP or source file was edited (REVIEW-RULES rule 1). Both lenses were applied. The diff from da3bf05 was read in full, and 49, 51 and 52 were reread in full. New and changed keys were checked against every file in the Q500 catalogue folder and against `src/samps` by grep. All items stay `reviewed: false`. This is an AI audit, not clinician verification.

## Result

| Id | Verdict | q1 | q2 | q3 | q4 | q5 |
|---|---|---|---|---|---|---|
| abdominal-pain-48 | PASS (unchanged) | PASS | PASS | PASS | PASS | |
| abdominal-pain-49 | PASS | PASS | PASS | PASS | | |
| abdominal-pain-50 | PASS (unchanged) | PASS | PASS | PASS | PASS | PASS |
| abdominal-pain-51 | FAIL | PASS | PASS | FAIL | FAIL | |
| abdominal-pain-52 | PASS | PASS | PASS | PASS | | |

Four SAMPs pass and one fails, on 2 of 19 questions. 51 q3 now has three fluoroquinolone distractors that fail for one shared reason, which leaves the key as the odd one out and no longer tests the key feature it is tagged with. The updates of 51 q3 and q4 also tell a mock-mode candidate that she was admitted, which is the q2 key (ruling B6).

Tests run by the reviewer: `SAMP_BATCH=s62 npx vitest run tests/samps.test.ts tests/samp-quality.test.ts tests/citations.test.ts` passed, 3 files, 124 of 124. `npx tsc --noEmit -p . | grep samps/s62` gave no output. The batch has 19 questions, 18 single and 1 menu (the writer's note says 18 and 17, a miscount that does not affect the file). Single key positions, first to fifth: 4, 3, 3, 4, 4 of 18 (highest 22 percent, every position used). The key is the single longest option in 4 of 18 singles (22 percent), and ties for longest in 2 more (49 q2 and 51 q4), 33 percent if ties count. Both are within the 35 percent limit, but with ties counted the margin is thin (ruling B1). The reviewer computed these with a throwaway script in the scratchpad.

## Fixes required by the previous verdict

| Previous fix | Applied | Comment |
|---|---|---|
| 49 q2 dose to 1 g IV, with a Canadian acetaminophen injection monograph as a third source | Yes | Key "acetaminophen 1000 mg IV". B. Braun monograph (DPD 00069718) added and cited on q2. Verified below. |
| 49 q3 remove or source "the contrast adds nothing to finding a stone" | Yes | Now "NICE recommends the low-dose noncontrast study, and a standard CT with IV contrast gives a larger dose", the wording the previous verdict offered. NICE NG118 1.1.3 says "consider low-dose non-contrast CT". That a standard-dose CT gives more radiation than a low-dose study is close to definition. Accepted. |
| 49 q4 wrong key feature tag, mock-mode cue, untrue reason | Yes, dropped | 49 now has 3 questions, which the coordinator ruled acceptable and SAMP_SPEC section 2 allows. |
| 51 q3 antibiotic spectrum claims need a source | Not as asked | The writer removed the spectrum claims and rebuilt the distractors instead of adding a source. The rebuild fails, see below. |
| 52 q3 replace the radiation statement item | Yes, dropped | 52 now has 3 questions. The ciprofloxacin item moved from q4 to q3 with its text unchanged. |

## Required fixes

### abdominal-pain-51

| Question | Field | Current text | Required change | Source | Confidence |
|---|---|---|---|---|---|
| q3 | options and explanation | Options "amoxicillin-clavulanate PO", "ciprofloxacin and metronidazole PO", "levofloxacin and metronidazole PO", "moxifloxacin PO alone", "No antibiotic until cultures return". All three fluoroquinolone options are rejected for one reason, the class tendon warning at age 69 on prednisone. | Three faults. (1) Cue. Three options in one drug class that share one flaw cannot each be the single best answer, so a test-wise candidate drops the cluster and the "No ..." option and picks the only other antibiotic. The key is then the odd one out and can be found without the clinical knowledge. (2) Key feature. Infectious diseases KF8 is choosing empiric antibiotics from the likely organisms. Every antibiotic option now covers gram-negative bacilli and anaerobes, so the item no longer tests organism-based choice. It tests one drug safety warning. (3) Support for the key. WSES 2020 describes amoxicillin-clavulanic acid only as the antibiotic arm of the DIABOLO trial. In the same way it describes oral and IV ciprofloxacin with metronidazole as the regimens of an oral versus IV trial. So WSES gives no reason to prefer the key, and nothing cited says that amoxicillin-clavulanate covers the organisms WSES asks for. The key is right only by elimination through the monograph. Required: keep "ciprofloxacin and metronidazole PO" as the one fluoroquinolone distractor (its monograph reason stands). Replace "levofloxacin and metronidazole PO" and "moxifloxacin PO alone" with non-fluoroquinolone oral regimens that fail for distinct reasons of organism coverage, for example "cefuroxime axetil PO" (no anaerobic cover) and "metronidazole PO alone" (no gram-negative cover). Add a fourth source, opened and verified by the writer, that states those coverage facts and the coverage of the key, for example a Canadian amoxicillin-clavulanate product monograph or an intra-abdominal infection guideline that lists amoxicillin-clavulanate alone, and a cephalosporin or fluoroquinolone with metronidazole, as oral regimens. Cite it on q3 and make every reason in the explanation trace to it, the monograph or WSES. Keep options alphabetical with "No antibiotic until cultures return" last, and recheck parity. The key stays first, so key positions do not change. | WSES 2020 full text (PMC7206757) read: "The antibiotic treatment was a 10-day course of IV amoxicillin-clavulanic acid ... After 48 h, the administration route could be switched to per os" and "Oral and intravenous regimens utilizing ciprofloxacin and metronidazole were compared." CFPC infectious diseases KF8. SAMP_SPEC sections 7, 8 and 13. Previous verdict 51 q3 row | Medium |
| q3 | update | "She is admitted. She is drinking fluids without vomiting and has no drug allergies." | Mock mode (ruling B6). "She is admitted" names the disposition in the q2 key ("Hospital admission with antibiotics"). q3 does not need it, because the oral regimen choice is the same wherever she is treated. Delete "She is admitted." so the update reads "She is drinking fluids without vomiting and has no drug allergies." | SCORING-RULINGS B6 | Medium |
| q4 | update | "She improves and is ready for discharge on the fourth day." | Mock mode (ruling B6). Discharge on the fourth day tells the candidate she was admitted, which narrows q2 to the key. q4 does not need it. Reword, for example "Her pain and tenderness settle over the next few days." The explanation ("After an episode treated without surgery") still holds. | SCORING-RULINGS B6 | Medium |

The two B6 rows were not raised in rounds 2 or 3. They are new findings of this fresh review, not reversals of a ruling. They go back with the q3 fix because 51 fails anyway. q4 is otherwise unchanged and correct.

## Questions the coordinator asked about

| Question | Ruling |
|---|---|
| 49 q2 key acetaminophen 1000 mg IV against DPD 00069718 | Correct. Monograph fetched and read (B. Braun of Canada, initial authorization 24 February 2023). The Serious Warnings box says "the dosing is based on weight for patients under 50 kg". Section 4.2 Table 1: adults and adolescents of 50 kg or more with no added hepatotoxicity factor take 650 mg every 4 hours or 1000 mg every 6 hours, maximum 4000 mg in 24 hours. Those of 50 kg or less take 12.5 mg/kg every 4 hours or 15 mg/kg every 6 hours. Indicated from 2 years of age. At 52 kg, 500 mg is below every dose the label gives her (15 mg/kg would be 780 mg). A 500 mg/50 mL product exists, so the underdose is plausibly wrong, not absurd. The explanation states all of this correctly. |
| 49 q2 NICE order | Correct. NICE NG118 fetched (HTTP 200). 1.2.2: "Offer intravenous paracetamol ... if NSAIDs are contraindicated or are not giving sufficient pain relief." 1.2.3: "Consider opioids ... if both NSAIDs and intravenous paracetamol are contraindicated or are not giving sufficient pain relief." The explanation's order is right. The ibuprofen and repeat ketorolac reason (a second NSAID dose 30 minutes after the first) is true. The analgesia-sedation KF3 tag (enough analgesia, combining agents, dose) fits well, and the underdose distractor sharpens that fit. |
| 49 q3 rewritten sentence | Supported. See the table above. |
| 51 q3 amoxicillin-clavulanate as single defensible key on WSES | Not sufficient on its own. The key is clinically right, and no other option is defensible as the best choice for a 69-year-old on prednisone. But WSES describes ciprofloxacin with metronidazole in exactly the same way (a trial regimen), so the WSES sentence does not single out the key. Failed above. |
| 51 q3 three fluoroquinolone distractors failing for one reason | Not acceptable. Each reason is true and sourced, but the cluster cues the key and moves the item off its key feature. Failed above. |
| 52 now 3 questions with the ciprofloxacin question as q3 | Accepted. The text is the round-3 q4 unchanged, which passed. The update "Imaging confirms a cause outside the urinary tract" names neither earlier key. KF8 fits. Both listed sources are still cited (tc-pe-dx on q1 and q2, pms-ciprofloxacin on q3). |

## Unrequested writer changes (REVIEW-RULES rule 4)

| Change | Verdict |
|---|---|
| 49 q2 codeine distractor replaced by "acetaminophen 500 mg IV", to balance key positions | Accepted. A label underdose is a fair test of the dose, and doses of one drug sit together from low to high (SAMP_SPEC section 7, ruling B12). Two doses of the key drug among five options is a mild convergence cue. It goes on the physician list, not a failure, because the spec expects same-drug dose options. |
| 49 q2 explanation lost the codeine and vomiting sentence | Accepted. That distractor no longer exists. |
| 49 source list now three sources | Accepted. Every source is cited (luchs q1, apapIv q2, nice q3). The citation names a body, a work and a year. |

## Checks with no change needed

- 48 and 50: no hunk in the diff from da3bf05. Unchanged since they passed.
- 49 q1 and q3: unchanged apart from the q3 sentence. 49 q3 tests KF7 honestly.
- 51 q1, q2 and q4 content: unchanged and verified in round 3. WSES text reread for the q3 judgement.
- 52 q1 and q2: unchanged. Wells arithmetic no longer appears in the SAMP (it lived in the dropped q3).
- Ciprofloxacin monograph (00067730) reread: "Fluoroquinolones including pms-CIPROFLOXACIN are associated with an increased risk of tendinitis and tendon rupture in all ages. The risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs". So the class claim in 51 q3 is true. The problem is the item design, not the fact.
- Key feature coverage, abdominal pain: KF1 50 q2, KF2 50 q4 and 51 q1, KF3 52 q1 and q2, KF4 50 q5, KF5 48 q2 and 50 q3, KF6 49 q1, KF7 49 q3, KF8 48 q1, 50 q1 and 52 q3. Every key feature is covered, and none depends on 51 q3 or q4.
- Key positions and longest-option rate: within spec (see above). The required 51 q3 fix keeps the key first.
- Uniqueness: no catalogue file or `src/samps` item keys IV acetaminophen 1000 mg as the step after an NSAID for renal colic. Catalogue hits for "acetaminophen 1 g IV" are items of multi-answer analgesic lists or a combination with fentanyl, not this decision. Amoxicillin-clavulanate is not keyed for diverticulitis elsewhere. abdominal-pain-24 q3 (s19) keys no antibiotics for an immunocompetent patient, the opposite branch. The ciprofloxacin-stop key is not keyed elsewhere.
- Mock mode: 49 q2 and q3 updates name no earlier key. The q3 ultrasound implies a stone is suspected, which is normal flow and does not confirm the q1 key. 52 q3 is clean.
- House style: no em or en dashes and no semicolons in the file. Canadian spelling. Lower-case generic drug names in options.

## Sources verified

- B. Braun of Canada. Acetaminophen Injection product monograph, 2023. https://pdf.hres.ca/dpd_pm/00069718.PDF fetched and read (indications, Serious Warnings box, section 4.2 Table 1).
- NICE NG118, 2019. https://www.nice.org.uk/guidance/ng118/chapter/Recommendations fetched (HTTP 200) and read: 1.1.3 and its rationale, 1.2.2, 1.2.3.
- Sartelli M et al. WSES 2020. Full text read through Europe PMC (PMC7206757): antibiotic coverage, oral route, DIABOLO regimen, oral versus IV ciprofloxacin with metronidazole trial.
- Pharmascience. pms-CIPROFLOXACIN product monograph, 2022. https://pdf.hres.ca/dpd_pm/00067730.PDF fetched and tendon warnings read.
- Unchanged and verified in earlier rounds: CFAS 2026, Luchs 2002, Ohle 2020, ACC/AHA 2022, Brandl 2016, Thrombosis Canada PE diagnosis 2025.

## Physician-level items (not grounds for failure)

1. 49 q2: the key follows NICE (IV acetaminophen before an opioid). Many Canadian EDs would give morphine at this point. The Canadian monograph indicates IV acetaminophen for "moderate to severe pain with adjunctive opioid analgesics", and her pain is 7 out of 10.
2. 49 q2: two acetaminophen doses among the options hint at the drug. The dose itself is still tested.
3. 51 q3: in mock mode a question about the antibiotic regimen implies that antibiotics were given, which narrows q2. It cannot work without that, so it is left and flagged under B6.
4. Items carried from earlier rounds still stand: 48 q3 NSAID cue, the loose off-topic fits in 48 q4 (shock KF3) and 51 q4 (infectious-diseases KF3), and 51 q3 keying oral therapy in an admitted immunosuppressed patient.

## Summary

Five SAMPs, 19 questions. abdominal-pain-48, -49, -50 and -52 pass. abdominal-pain-51 fails on 2 questions:
- 51 q3: the three fluoroquinolone distractors share one flaw, which cues the key and moves the item off infectious diseases KF8. WSES does not single out the key. Restore organism-coverage distractors and add a verified fourth source. Delete "She is admitted." from the update.
- 51 q4: reword the update so it does not reveal admission.

The 49 q2 dose, the 49 q3 sentence and the two dropped questions are confirmed. Every key feature is covered, and key positions and the longest-option rate are within spec. The s62 batch has not yet passed fresh review. 51 goes back to a writer, and its revision needs another fresh independent review.
